Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Diabetic Nephropathy | Research article

Arg913Gln variation of SLC12A3 gene is associated with diabetic nephropathy in type 2 diabetes and Gitelman syndrome: a systematic review

Authors: Eduardo De la Cruz-Cano, Cristina del C. Jiménez-González, Vicente Morales-García, Conny Pineda-Pérez, Juan G. Tejas-Juárez, Francisco J. Rendón-Gandarilla, Silvia Jiménez-Morales, José A. Díaz-Gandarilla

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Diabetic nephropathy is a global common cause of chronic kidney disease and end-stage renal disease. A lot of research has been conducted in biomedical sciences, which has enhanced understanding of the pathophysiology of diabetic nephropathy and has expanded the potential available therapies. An increasing number of evidence suggests that genetic alterations play a major role in development and progression of diabetic nephropathy. This systematic review was focused on searching an association between Arg913Gln variation in SLC12A3 gene with diabetic nephropathy in individuals with Type 2 Diabetes and Gitelman Syndrome.

Methods

An extensive systematic review of the literature was completed using PubMed, EBSCO and Cochrane Library, from their inception to January 2018. The PRISMA guidelines were followed and the search strategy ensured that all possible studies were identified to compile the review. Inclusion criteria for this review were: 1) Studies that analyzed the SLC12A3 gene in individuals with Type 2 Diabetes and Gitelman Syndrome. 2) Use of at least one analysis investigating the association between the Arg913Gln variation of SLC12A3 gene with diabetic nephropathy. 3) Use of a case–control or follow-up design. 4) Investigation of type 2 diabetes mellitus in individuals with Gitelman’s syndrome, with a history of diabetic nephropathy.

Results

The included studies comprised 2106 individuals with diabetic nephropathy. This review shows a significant genetic association in most studies in the Arg913Gln variation of SLC12A3 gene with the diabetic nephropathy, pointing out that the mutations of this gene could be a key predictor of end-stage renal disease.

Conclusions

The results showed in this systematic review contribute to better understanding of the association between the Arg913Gln variation of SLC12A3 gene with the pathogenesis of diabetic nephropathy in individuals with T2DM and GS.
Appendix
Available only for authorised users
Literature
1.
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63(4):1499–507.CrossRefPubMed
2.
Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006;6(6):479–83.CrossRefPubMed
3.
Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl. 2005;98:S7–s10.CrossRef
4.
Bener A, Al-Laftah F, Al-Hamaq AO, Daghash M, Abdullatef WK. A study of diabetes complications in an endogamous population: an emerging public health burden. Diabetes Metab Syndr. 2014;8(2):108–14.CrossRefPubMed
5.
Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R. Healthcare resource use, costs, and disease progression associated with diabetic nephropathy in adults with type 2 diabetes: a retrospective observational study. Diabetes Ther. 2017;8(3):555–71.CrossRefPubMedPubMedCentral
6.
Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311(24):2518–31.CrossRefPubMedPubMedCentral
7.
Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrol Dial Transplant. 2016;31(9):1425–36.CrossRefPubMed
8.
Low S, Lim SC, Yeoh LY, Liu YL, Liu JJ, Fun S, Su C, Zhang X, Subramaniam T, Sum CF. Effect of long-term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: insights from the diabetic nephropathy cohort in Singapore. J Diabetes. 2016.
9.
Carrero JJ, Grams ME, Sang Y, Arnlov J, Gasparini A, Matsushita K, Qureshi AR, Evans M, Barany P, Lindholm B, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017;91(1):244–51.CrossRefPubMed
10.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, et al. Effect of Finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. Jama. 2015;314(9):884–94.CrossRefPubMed
11.
Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83(1):114–20.CrossRefPubMed
12.
Sternlicht H, Bakris GL. Management of Hypertension in diabetic nephropathy: how Low should we go? Blood Purif. 2016;41(1–3):139–43.CrossRefPubMed
13.
Eid AA, Ford BM, Bhandary B, de Cassia CR, Block K, Barnes JL, Gorin Y, Choudhury GG, Abboud HE. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes. 2013;62(8):2935–47.CrossRefPubMedPubMedCentral
14.
15.
Marshall CB. Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? Am J Physiol Renal Physiol. 2016;311(5):F831–f843.CrossRefPubMed
16.
Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS. Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes. 2005;54(11):3305–18.CrossRefPubMed
17.
18.
Kriz W, Lowen J, Federico G, van den Born J, Grone E, Grone HJ. Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy. Am J Physiol Renal Physiol. 2017;312(6):F1101–f1111.CrossRefPubMed
19.
Bai X, Hou X, Tian J, Geng J, Li X. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARgamma pathway. Oncotarget. 2016;7(24):36510–28.CrossRefPubMedPubMedCentral
20.
Sowers KM, Habibi J, Hayden MR. Diabetic nephropathy and tubulointerstitial fibrosis in cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2007;2(2):143–8.CrossRefPubMed
21.
Moeller MJ, Smeets B. Role of parietal epithelial cells in kidney injury: the case of rapidly progressing glomerulonephritis and focal and segmental glomerulosclerosis. Nephron Exp Nephrol. 2014;126(2):97.CrossRefPubMed
22.
Wang M, Zhang X, Song X, Zou X, Wu W, Wang Y, Lin B, Li R, Hu F, Zhao H. Nodular glomerulosclerosis and renin angiotensin system in Chinese patients with type 2 diabetes. Mol Cell Endocrinol. 2016;427:92–100.CrossRefPubMed
23.
Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, Tanaka Y, Fujioka T, Kaku K, Kawamori R, et al. Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes. 2003;52(11):2848–53.CrossRefPubMed
24.
Ng DP, Nurbaya S, Choo S, Koh D, Chia KS, Krolewski AS. Genetic variation at the SLC12A3 locus is unlikely to explain risk for advanced diabetic nephropathy in Caucasians with type 2 diabetes. Nephrol Dial Transplant. 2008;23(7):2260–4.CrossRefPubMed
25.
Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M, et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes. 2005;54(4):1171–8.CrossRefPubMed
26.
Mastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, Ballabio A, Casari G. Molecular cloning, expression pattern, and chromosomal localization of the human Na-cl thiazide-sensitive cotransporter (SLC12A3). Genomics. 1996;35(3):486–93.CrossRefPubMed
27.
Gamba G. The thiazide-sensitive Na+−cl- cotransporter: molecular biology, functional properties, and regulation by WNKs. Am J Physiol Renal Physiol. 2009;297(4):F838–48.CrossRefPubMedPubMedCentral
28.
Hebert SC. Roles of Na-K-2Cl and Na-cl cotransporters and ROMK potassium channels in urinary concentrating mechanism. Am J Phys. 1998;275(3 Pt 2):F325–7.
29.
Gamba G. Molecular biology of distal nephron sodium transport mechanisms. Kidney Int. 1999;56(4):1606–22.CrossRefPubMed
30.
Azak A, Huddam B, Kocak G, Ortabozkoyun L, Uzel M, Duranay M. Gitelman syndrome complicated with dysglycemia. Acta Diabetol. 2011;48(3):249–50.CrossRefPubMed
31.
32.
Yuan T, Jiang L, Chen C, Peng X, Nie M, Li X, Xing X, Li X, Chen L. Glucose tolerance and insulin responsiveness in Gitelman syndrome patients. Endocrine connections. 2017;6(4):243–52.CrossRefPubMedPubMedCentral
33.
Ren H, Qin L, Wang W, Ma J, Zhang W, Shen PY, Shi H, Li X, Chen N. Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. Am J Nephrol. 2013;37(2):152–7.CrossRefPubMed
34.
Subasinghe CJ, Sirisena ND, Herath C, Berge KE, Leren TP, Bulugahapitiya U, Dissanayake VHW. Novel mutation in the SLC12A3 gene in a Sri Lankan family with Gitelman syndrome & coexistent diabetes: a case report. BMC Nephrol. 2017;18(1):140.CrossRefPubMedPubMedCentral
35.
Tseng MH, Yang SS, Hsu YJ, Fang YW, Wu CJ, Tsai JD, Hwang DY, Lin SH. Genotype, phenotype, and follow-up in Taiwanese patients with salt-losing tubulopathy associated with SLC12A3 mutation. J Clin Endocrinol Metab. 2012;97(8):E1478–82.CrossRefPubMed
36.
Colussi G, Rombola G, Brunati C, De Ferrari ME. Abnormal reabsorption of Na+/CI- by the thiazide-inhibitable transporter of the distal convoluted tubule in Gitelman's syndrome. Am J Nephrol. 1997;17(2):103–11.CrossRefPubMed
37.
Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol. 2011;26(10):1789–802.CrossRefPubMedPubMedCentral
38.
39.
De Jong JC, Van Der Vliet WA, Van Den Heuvel LP, Willems PH, Knoers NV, Bindels RJ. Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman's syndrome. J Am Soc Nephrol. 2002;13(6):1442–8.CrossRefPubMed
40.
Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int. 2001;59(2):710–7.CrossRefPubMed
41.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London, England). 2010;8(5):336–41.CrossRef
42.
Kim JH, Shin HD, Park BL, Moon MK, Cho YM, Hwang YH, Oh KW, Kim SY, Lee HK, Ahn C, et al. SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. Diabetes. 2006;55(3):843–8.CrossRefPubMed
43.
Abu Seman N, He B, Ojala JR, Wan Mohamud WN, Ostenson CG, Brismar K, Gu HF. Genetic and biological effects of sodium-chloride cotransporter (SLC12A3) in diabetic nephropathy. Am J Nephrol. 2014;40(5):408–16.CrossRefPubMed
44.
Yadav AK, Kumar V, Dutta P, Bhansali A, Jha V. Variations in CCR5, but not HFE, ELMO1, or SLC12A3, are associated with susceptibility to kidney disease in north Indian individuals with type 2 diabetes. J Diabetes. 2014;6(6):547–55.CrossRefPubMed
45.
Nishiyama K, Tanaka Y, Nakajima K, Mokubo A, Atsumi Y, Matsuoka K, Watada H, Hirose T, Nomiyama T, Maeda S, et al. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/a: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia. 2005;48(7):1335–8.CrossRefPubMed
46.
Bodhini D, Chidambaram M, Liju S, Revathi B, Laasya D, Sathish N, Kanthimathi S, Ghosh S, Anjana RM, Mohan V, et al. Association of rs11643718 SLC12A3 and rs741301 ELMO1 variants with diabetic nephropathy in south Indian population. Ann Hum Genet. 2016;80(6):336–41.CrossRefPubMed
47.
Zhao W, Liu L, Zheng T, Li M, Wang N, Wang F. Relationship between SLCl2A3 gene Arg913Gin polymorphism and type 2 diabetic nephropathy in Han population of Shanghai. J Shanghai Jiaotong University (Med Sci). 2009;29(7):828–33.
48.
Zhang R, Zhuang L, Li M, Zhang J, Zhao W, Ge X, Chen Y, Wang F, Wang N, Bao Y et al: Arg913Gln of SLC12A3 gene promotes development and progression of end-stage renal disease in Chinese type 2 diabetes mellitus. 2017.
49.
Balavoine AS, Bataille P, Vanhille P, Azar R, Noel C, Asseman P, Soudan B, Wemeau JL, Vantyghem MC. Phenotype-genotype correlation and follow-up in adult patients with hypokalaemia of renal origin suggesting Gitelman syndrome. Eur J Endocrinol. 2011;165(4):665–73.CrossRefPubMed
50.
Gil-Pena H, Coto E, Santos F, Espino M, Cea Crespo JM, Chantzopoulos G, Komianou F, Gomez J, Alonso B, Iglesias S et al: A new SLC12A3 founder mutation (p.Val647Met) in Gitelman’s syndrome patients of Roma ancestry. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2017.
51.
Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007;2(2):366–73.CrossRefPubMed
52.
Dronavalli S, Bakris GL. Mechanistic insights into diuretic-induced insulin resistance. Hypertension. 2008;52(6):1009–11.CrossRefPubMed
53.
Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993;21(6 Pt 2):1024–9.CrossRefPubMed
54.
Paolisso G, Sgambato S, Gambardella A, Pizza G, Tesauro P, Varricchio M, D'Onofrio F. Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr. 1992;55(6):1161–7.CrossRefPubMed
Metadata
Title
Arg913Gln variation of SLC12A3 gene is associated with diabetic nephropathy in type 2 diabetes and Gitelman syndrome: a systematic review
Authors
Eduardo De la Cruz-Cano
Cristina del C. Jiménez-González
Vicente Morales-García
Conny Pineda-Pérez
Juan G. Tejas-Juárez
Francisco J. Rendón-Gandarilla
Silvia Jiménez-Morales
José A. Díaz-Gandarilla
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1590-9

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue

Research article

Association of plasma macrophage colony-stimulating factor with cardiovascular morbidity and all-cause mortality in chronic hemodialysis patients

Research article

An evaluation of phase angle, bioelectrical impedance vector analysis and impedance ratio for the assessment of disease status in children with nephrotic syndrome

Research article

Urinary angiostatin: a novel biomarker of kidney disease associated with disease severity and progression

Research article

Higher serum uric acid level is inversely associated with renal function assessed by cystatin C in a Japanese general population without chronic kidney disease: the KOBE study

Research article

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study

Case report

Simultaneous occurrence of IgG4-related Tubulointerstitial nephritis and colon adenocarcinoma with hepatic metastasis: a case report and literature review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits